2 weeks Ago By Defense World Staff
Clene Inc. ( NASDAQ:CLNN – Get Free Report ) insider Mark Mortenson acquired 20,512 shares of the firm’s stock in a transaction dated Monday, September 30th. The stock was purchased at an average cost of $4.
75 per share, with a total value of $97,432.00. Following the completion of the acquisition, the insider now directly owns 28,949 shares of the company’s stock, valued at approximately $137,507.
75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . Clene Stock Performance Shares of Clene stock traded up $0.
01 during trading hours on Tuesday, hitting $4.60. 55,205 shares of the company were exchanged, compared to its average volume of 72,016.
The business has a 50-day moving average of $5.16 and a 200-day moving average of $6.53.
Clene Inc. has a 1 year low of $3.82 and a 1 year high of $13.
20. The company has a current ratio of 0.99, a quick ratio of 0.
99 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $29.
76 million, a price-to-earnings ratio of -0.50 and a beta of 0.49.
Clene ( NASDAQ:CLNN – Get Free Report ) last released its earnings results on Wednesday, August 7th. The company reported ($1.06) EPS for the quarter, topping the consensus estimate of ($1.
60) by $0.54. Clene had a negative net margin of 6,890.
50% and a negative return on equity of 315.97%. The company had revenue of $0.
09 million during the quarter, compared to analysts’ expectations of $0.10 million. As a group, analysts expect that Clene Inc.
will post -5.26 EPS for the current fiscal year. Institutional Investors Weigh In On Clene Wall Street Analyst Weigh In Several research firms recently commented on CLNN.
HC Wainwright reiterated a “buy” rating and issued a $31.00 price target on shares of Clene in a research report on Monday, September 16th. EF Hutton Acquisition Co.
I raised shares of Clene to a “strong-buy” rating in a report on Tuesday, September 10th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $94.00 price target on shares of Clene in a report on Tuesday, August 6th.
View Our Latest Analysis on CLNN Clene Company Profile ( Get Free Report ) Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. See Also Five stocks we like better than Clene How to Effectively Use the MarketBeat Ratings Screener Why Lennar Stock Could Be the Best Play in the Housing Market 3 Stocks to Consider Buying in October 2 Energy Stocks Fueling the AI Datacenter Boom 5 discounted opportunities for dividend growth investors Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech? Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.
com's FREE daily email newsletter ..
